REGN Q1 2017 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.3B+9.8% YoY

Gross Profit

$1.2B90.7% margin

Operating Income

$431M32.6% margin

Net Income

$249M18.9% margin

EPS (Diluted)

$2.16

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

$356M

Free Cash Flow

$305M

Stock-Based Comp.

$134M

Balance Sheet

Total Assets

$7.8B

Total Liabilities

$3.0B

Stockholders' Equity

$4.9B

Cash & Equivalents

$812M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.2B	+9.8%
Gross Profit	$1.2B	$1.1B	+9.9%
Operating Income	$431M	$329M	+30.7%
Net Income	$249M	$166M	+50.2%

Revenue Segments

Antibody Collaboration

$132M63%

Immuno-oncology Agreement

$79M37%